Candel Therapeutics, Inc. (CADL) stock
Close on Nov 11, 2026Market cap $705.50MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $705.50M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.59
- Dividend yield
- –
- Free cash flow yield
- -8.12%
Fundamentals
- Net income
- -$88.53M
- EPS, diluted
- -$1.41
- Free cash flow
- -$57.32M
- Book value per share
- $1.70
- Diluted shares
- 74M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $9.35
- Open
- $9.53
- Day's range
- $9.18 – $9.54
- Volume
- 1,096,934
- Average volume (20 days)
- 1,117,769
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.00
- 52-week range
- $4.35 – $14.00
- RSI (14 days)
- 51.2
- Volatility (1 year)
- 72.6%
- Relative volume
- 0.92×
- WACC
- 9.9%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CADL | S&P 500 | Difference | CADL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.2% | -2.4% | −4.8 pts | ||
| 3 months | -13.4% | -1.2% | −12.3 pts | ||
| Year to date | +63.2% | +12.3% | +50.9 pts | ||
| 1 year | +83.7% | +12.4% | +71.2 pts | ||
| 3 years | +921.0% | +78.8% | +842.2 pts | +116.9% | +21.4% |
| 5 years | -15.8% | +75.2% | −91.0 pts | -3.4% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Candel Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Update
- Results
About Candel Therapeutics
Biological Products, (No Diagnostic Substances)
Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies designed to stimulate systemic immune responses against cancer. Its investigational pipeline features two primary clinical candidates: aglatimagene besadenovec, an adenovirus-based therapy evaluated for localized prostate cancer, non-small cell lung cancer, and pancreatic cancer, and linoserpaturev, a herpes simplex virus construct being evaluated for recurrent high-grade glioma. The company also engineers early-stage solid tumor candidates using its enLIGHTEN discovery platform. Its target patients include individuals with solid tumors, especially those showing limited responses to standard oncology treatments.
Company profile, executives and historyCandel Therapeutics stock: common questions
What is Candel Therapeutics's stock price?
CADL closed at $9.22 on Nov 11, 2026, down 1.39% on the day. Over the past 52 weeks it traded between $4.35 and $14.00.
What is Candel Therapeutics's market cap?
Candel Therapeutics was worth $705.50M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CADL's P/E ratio?
Candel Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.41), so it has no meaningful P/E ratio.
Does Candel Therapeutics pay a dividend?
No. Candel Therapeutics has not paid a cash dividend over the last twelve months.
When does Candel Therapeutics report earnings next?
Candel Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CADL stock performed over the past year?
Including dividends, CADL returned +83.7% over the past year, against +12.4% for the S&P 500.
How many CADL shares are sold short?
13M shares were sold short at the latest FINRA report, 18.86% of the float, or 13.3 days of average trading volume.
Who are Candel Therapeutics's competitors?
Companies most similar to Candel Therapeutics by business, industry and size include REPL, ESLA, CLDI, ALLO, VIR.
See a number that looks wrong?